arrow
A

Aditi Shastri

Montefiore Einstein Comprehensive Cancer Center
H指数:24
被引数:2,056

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Exploiting an epigenetic resistance mechanism to PI3-kinase inhibition in leukemic stem cells

利用表观遗传耐药机制克服白血病干细胞中PI3-激酶抑制

Leukemia
IF13.4
2026-09-280
OAAI
Graft-versus-host disease prophylaxis with abatacept plus intermediate dose cyclophosphamide for GVHD prophylaxis after peripheral blood stem transplantation: a single institution study

阿巴西特联合中剂量环磷酰胺预防异基因造血干细胞移植后移植物抗宿主病:一项单中心研究

2026-07-270
PRE
Chromatin rewiring of β-globin and MYC enhancers by TGF-β1 drives defective erythropoiesis

TGF-β1通过重塑β-球蛋白和MYC增强子染色质驱动缺陷性红细胞生成

2026-05-130
OAAI
A STAT3 degrader demonstrates efficacy in venetoclax resistant acute myeloid leukemia

STAT3降解剂在Venetoclax耐药急性髓系白血病中显示出疗效

Leukemia
IF13.4
2026-02-170
OAAI
Metronomic low-dose regimen of decitabine and venetoclax is safe and reduces monocyte burden in chronic myelomonocytic leukemia

去甲基化药物地西他滨与维奈克拉低剂量密集联合方案安全且可减轻慢性髓单核细胞白血病的单核细胞负荷

2026-01-010
PRE
Assessing the performance of the Iceland screens, treats, or prevents multiple myeloma (iStopMM) model in a multicultural Bronx cohort: implications for monoclonal gammopathy of undetermined significance risk stratification

评估冰岛筛查、治疗或预防多发性骨髓瘤(iStopMM)模型在多元文化布朗克斯队列中的表现:对未定意义单克隆丙种球蛋白病的风险分层的影响

2025-08-210
OAAI
Adding the FcRn antagonist efgartigimod for the prevention of IgG-mediated complications in the peri-transplant period

添加FcRn拮抗剂efgartigimod以预防移植围手术期IgG介导的并发症

2025-08-050
PRE
Promising Safety and Efficacy Data for Peginterferon Alfa-2a (PEG-IFN) and Bictegravir/Emtricitabine/Tenofovir Alafenamide (Biktarvy) in a North American Adult T-Cell Leukemia Lymphoma (NA-ATLL) Cohort of Patients

Peginterferon Alfa-2a(PEG-IFN)和Bictegravir/Emtricitabine/Tenofovir Alafenamide(Biktarvy)在北美成人T细胞白血病/淋巴瘤(NA-ATLL)患者队列中的安全性和有效性数据表现出前景。

BLOOD
IF23.1
2024-11-050
PRE
Metronomic Low-Dose Regimen of Decitabine and Venetoclax Is Safe and Efficacious for Chronic Myelomonocytic Leukemia

低剂量地西他滨联合维奈克拉的间质给药方案对慢性骨髓单核细胞白血病的治疗是安全且有效的。

BLOOD
IF23.1
2024-11-050
PRE
RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in TET2-Mutated Clonal Hematopoiesis
2024-08-270
PRE
Immunotherapy-resistant acute lymphoblastic leukemia cells exhibit reduced CD19 and CD22 expression and BTK pathway dependency
2024-02-201
OAAI
Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study
2024-01-0115
PRE